FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

Authors :: Horwitz, S.M.
Scarisbrick, J.
Prince, H.M.
Whittaker, S.
Duvic, M.
Kim, Y.H.
Quaglino, P.
Zinzani, P.L.
Bechter, O.
Eradat, H.
Pinter‐Brown, L.
Akilov, O.
Geskin, L.
Sanches, J.
Ortiz‐Romero, P.
Lisano, J.
Brown, L.
Palanca‐Wessels, M.C.
Gautam, A.
Bunn, V.
Source :: Hematological Oncology; Jun2019 Supplement S2, Vol. 37, p286-288, 3p
Publication Year :: 2019

Full Text Access

Tools